Do You Actually Need a New Clinical Study?
Before committing time and budget to a clinical investigation, Bioexcel reviews your existing clinical evidence, device risk, claims, PMS, PMCF, literature, Risk Management and regulatory feedback to identify the real evidence gap.
The result is a practical clinical evidence roadmap showing what can be used, what is missing and what evidence-generation option is proportionate to the question.
What Is a Medical Device Clinical Evidence Gap Assessment?
A clinical evidence gap assessment compares the clinical evidence currently available for a medical device with the evidence needed to support its intended purpose, clinical claims, safety, performance, benefit-risk and target regulatory pathway.
The assessment helps determine whether the gap can be addressed through: existing evidence, improved analysis, CER remediation, PMCF, retrospective data, registry/RWE, or a new clinical investigation.
Bioexcel Lifesciences & Research LLP provides medical device and IVD clinical evidence gap assessments to identify whether existing evidence is sufficient or whether additional clinical investigation, PMCF, retrospective evidence, registry data, IVD performance studies or documentation remediation may be required.
Do Not Start With “What Study Should We Run?”
Start with: “What clinical question remains unanswered?”
Outcome A — Evidence Sufficient
No new clinical study may be needed.
Outcome B — Documentation Gap
Existing evidence may be adequate, but the CER/CEP/PER needs strengthening.
Outcome C — Analysis Gap
Existing data need better statistical or clinical analysis.
Outcome D — Post-Market Gap
PMCF / registry / RWE may be appropriate.
Outcome E — Clinical Evidence Gap
A new clinical investigation may be required.
Knowing which outcome applies before committing to a study is the fastest way to avoid an unnecessary — and expensive — new clinical investigation.
From Existing Evidence to the Minimum Defensible Evidence Strategy
Define the Product
Assess: Device / IVD, Intended purpose, Claims, Classification, Target market, Patient population
Review Existing Evidence
Review: Existing clinical studies, Literature, PMS, PMCF, Complaints, Registries, RWE, Equivalent/similar-device data
Review Risk & Benefit
Assess: Clinical risks, Residual risks, Benefit claims, Risk Management, SOTA
Identify the Gap
Classify as: Documentation, Analysis, Clinical evidence, Post-market, Traceability, Regulatory alignment
Select the Evidence Path
Potential outcome: No New Study, CER/PER Remediation, Retrospective PMCF, Prospective PMCF, Registry/RWE, Clinical Investigation, or IVD Clinical Performance Study
Create Roadmap
Output: Clinical Evidence Strategy & Action Plan
What the Assessment Covers
- Intended purpose and clinical or performance claims
- Applicable GSPRs
- Existing clinical or performance evidence
- CEP/CER or PEP/PER
- Scientific validity and analytical performance
- Equivalence or similarity rationale
- Risk-management and benefit–risk linkage
- PMS, PMCF, PMPF and PSUR
- Evidence traceability across affected documents
This is the entry-level engagement from which larger CER, PER, PMCF and clinical-study projects are generated.
What Documents Bioexcel Can Review
Not Every Clinical Gap Is a Missing Clinical Study
Bioexcel should classify gaps into clear categories.
Documentation Gap
Evidence exists but is poorly documented.
Examples
Analysis Gap
Data exist but are inadequately analyzed.
Examples
Clinical Evidence Gap
Actual device-specific evidence is insufficient.
Possible solution
Post-Market Gap
Lifecycle evidence is insufficient.
Possible solution
Equivalence Gap
Evidence relies heavily on another device but equivalence cannot be sufficiently supported.
Regulatory Alignment Gap
Evidence exists but does not answer the current MDR/IVDR requirement.
Does Every EU MDR Clinical Evidence Gap Require a New Clinical Investigation?
No. Some gaps can be addressed through improved clinical evaluation, stronger literature appraisal, better PMS/PMCF integration, statistical reanalysis, retrospective clinical evidence, registry data or targeted post-market activities. A new clinical investigation should be considered when the remaining clinical question cannot be adequately answered by the available evidence.
Is the Problem the Evidence—or the Way the Evidence Is Presented?
Existing Evidence Adequate
→ CER remediation
Evidence Partially Adequate
→ targeted evidence generation
Evidence Insufficient
→ new clinical strategy
Start With Root Cause, Not Just the Wording of the Finding
A finding may say: “Insufficient clinical evidence.”
But the Root Cause May Actually Be
Can Bioexcel Tell Whether a Notified Body Finding Requires a New Study?
Yes. Bioexcel can assess the underlying clinical evidence issue and determine whether the finding may be addressed through documentation remediation, additional analysis, PMCF, retrospective data, registry evidence or a new clinical investigation.
Do You Need a New Clinical Investigation? — Decision Factors
- the device is novel
- important clinical claims lack device-specific support
- residual risks remain clinically uncertain
- equivalence cannot be substantiated
- existing data are not applicable
- long-term performance is unknown
- regulators specifically require additional data
- a pivotal clinical question remains unanswered
But the decision should be study and device specific.
Learn more about how Bioexcel plans and runs a clinical investigation once the gap assessment confirms one is required.
When a New Study May Not Be Necessary
- Existing device-specific studies adequately answer the clinical question.
- Strong PMCF data are already available.
- Existing registry/RWE provides appropriate evidence.
- The problem is primarily poor CER methodology.
- Existing data require reanalysis rather than recollection.
- The issue is traceability, not clinical evidence quantity.
Core Website Message
Bioexcel does not recommend a clinical study simply because a clinical gap exists. We first identify whether new patient data are actually required.
This is a strong differentiation point.
Can Existing Hospital Records Answer the Question?
- Historical device use
- Patient identification
- Device traceability
- Endpoint availability
- Follow-up
- Imaging/lab data
- Revision/reintervention data
- Ethics/privacy access
Retrospective PMCF may avoid unnecessary prospective recruitment.
When Is Retrospective PMCF Appropriate?
Retrospective PMCF may be appropriate when the device has already been used clinically and historical records provide sufficiently reliable device exposure, outcomes, follow-up and source documentation to answer the identified post-market clinical question.
When New Follow-Up Is More Appropriate
- historical records are incomplete
- endpoints were not routinely documented
- PROMs are required
- standardized imaging is needed
- long-term data need structured collection
- current device version needs direct evidence
When the Question Requires Ongoing Real-World Surveillance
When Confirmatory Evidence Is Required
For Novel Technologies With Limited Human Evidence
- Is preclinical evidence sufficient?
- What safety uncertainty remains?
- What should initial cohort size be?
- Should enrollment be staged?
- What stopping rules are needed?
Does the IVD Have Sufficient Clinical Performance Evidence?
Potential Outcomes
Can Bioexcel Assess Whether an IVD Needs a New Clinical Performance Study?
Yes. Bioexcel can review the existing scientific validity, analytical and clinical performance evidence, intended purpose, population, specimen strategy and comparator framework to identify whether additional clinical performance data are needed.
Is the Clinical Evidence Strong but the User Evidence Weak?
Algorithm Performance Is Not the Whole Evidence Package
Potential Outcomes
Sometimes the Study Is Fine—the Analysis Is Not
Can Another Device's Clinical Data Support Your Device?
Equivalence Supportable
Use evidence appropriately.
Similarity Only
Evidence may support SOTA but not necessarily device equivalence.
Equivalence Not Supportable
Additional device-specific evidence may be required.
Is the Device Being Compared to the Right Clinical Benchmark?
A weak SOTA can make an otherwise reasonable CER appear clinically unsupported.
Which GSPRs Actually Need Clinical Evidence?
This improves traceability and may reveal that the issue is documentation rather than lack of evidence.
Are the Clinical Risks Actually Supported by Clinical Data?
Risk Management says: “Rare” but no clinical evidence supports the frequency.
This may create a clinical evidence gap.
Is the Post-Market Data Being Used Properly?
Questions
Is PMS linked to CER?
Are rates normalized appropriately?
Are new clinical risks emerging?
Is PMCF responding to PMS signals?
Does the PSUR Reflect the Clinical Evidence Story?
Bioexcel can assess cross-document consistency.
One Device Should Not Have Five Different Clinical Stories
IFU ↔ Risk Management ↔ CER ↔ PMCF ↔ PMS ↔ PSUR ↔ SSCP
Potential Inconsistencies
Do You Need a European Clinical Study?
Not necessarily.
The Key Question Is Whether the Available Evidence Is
European Data May Be Particularly Valuable Where
Can Indian Clinical Data Support EU MDR?
Potentially yes.
Indian Clinical Data May Contribute When
Important
Do not state that Indian data are automatically accepted for EU MDR.
Can Clinical Data Generated in India Be Used for EU MDR?
Potentially yes. Clinical data generated in India may support an EU MDR evidence package when the data are scientifically valid, clinically relevant, appropriately generated and applicable to the intended European use and population. Regulatory suitability should be assessed case by case.
Evidence Gap Matrix
| Evidence Area | Current Status | Gap | Risk | Recommended Action |
|---|---|---|---|---|
| Device-specific clinical data | Partial | Long-term follow-up | High | PMCF |
| Literature | Weak | Search/appraisal | Medium | CER remediation |
| Equivalence | Limited | Data access | High | Reassess |
| PMS | Available | Poor CER linkage | Medium | Integrate |
| Risk Management | Available | Frequency evidence | Medium | Clinical alignment |
| Clinical claim | Partially supported | Outcome data | High | Targeted evidence |
Do not use actual client data in public examples.
Not Every Gap Has the Same Regulatory Risk
Critical
Could undermine safety, benefit-risk or conformity.
High
Material evidence issue likely to require action.
Medium
Important documentation or analysis gap.
Low
Minor consistency or presentation issue.
This helps sponsors prioritize budget and timeline.
Gap → Action Matrix
Gap
Insufficient long-term implant data
Recommendation
PMCF / registry
Gap
Strong existing study, weak statistical interpretation
Recommendation
Reanalysis
Gap
Poor CER literature methodology
Recommendation
CER remediation
Gap
No device-specific evidence
Recommendation
Clinical investigation
Gap
Historical hospital data available
Recommendation
Retrospective PMCF feasibility
Gap
IVD lacks intended-user evidence
Recommendation
Layperson study
Final Output Should Be More Than a Gap List
Bioexcel should provide a prioritized roadmap:
Immediate
Fix documentation / response risk.
Short Term
Generate targeted evidence.
Medium Term
PMCF / registry.
Lifecycle
PMS + CER updates.
- 0–3 Months: Documentation remediation
- 3–12 Months: Targeted study / PMCF
- 12+ Months: Registry / lifecycle evidence
Timelines should remain indicative and study-specific.
Generate Only the Evidence That Is Needed
The objective of a gap assessment is not to recommend the largest study. It is to identify the most proportionate evidence strategy that can credibly answer the regulatory question.
Potential Savings May Come From
Important
Do not promise fixed cost savings.
Can a Clinical Evidence Gap Assessment Reduce Unnecessary Study Costs?
Potentially yes. A structured review can identify whether existing data, retrospective evidence, statistical reanalysis, PMCF or documentation remediation can address the evidence question before a larger prospective study is initiated.
For Manufacturers With an Active Regulatory Deadline
Day 1
Documents received
Review
Finding + supporting evidence
Output
Root-cause and evidence strategy
Priority review pathways can be discussed for time-sensitive Notified Body findings.
Strategic Review With the Sponsor Team
Potential Participants
Workshop Topics
Clinical Evidence Strategy Report
- Device & Intended Purpose
- Regulatory Objective
- Existing Evidence Inventory
- Clinical Claims
- Clinical Risks
- SOTA
- Evidence Adequacy Assessment
- Gap Matrix
- Root-Cause Analysis
- Evidence Options
- Recommended Strategy
- Priority Ranking
- Indicative Study Architecture
- Next Steps
Turn the Gap Into a Draft Study Strategy
If new evidence is recommended, Bioexcel can additionally provide:
This moves the sponsor directly from strategy into proposal/feasibility.
Once the Study Is Defined, Test Whether It Can Actually Be Executed
One Assessment Can Lead Into Full Execution
This should be the conversion architecture for the page.
No Obligation to Award the Clinical Study
Bioexcel can provide the clinical evidence gap assessment as a standalone consulting engagement.
The Sponsor May Then
This makes the consulting offer more credible.
Why Manufacturers Use Bioexcel for Clinical Evidence Strategy
MedTech Specialization
Assessment is centered on medical device and IVD evidence rather than generic trial strategy.
Clinical + Regulatory View
CER, PMCF, PMS, Risk Management and clinical investigations are reviewed together.
Evidence-First Approach
A new study is recommended only when the clinical question requires one.
Retrospective + Prospective Options
Existing data are considered before new enrollment.
Biostatistics Integration
Existing datasets can be evaluated for reanalysis potential.
End-to-End Execution
If new evidence is needed, Bioexcel can continue into feasibility and study delivery.
Clinical Evidence Strategy Deliverables
Depending on scope:
- Clinical Evidence Gap Assessment
- Regulatory Evidence Inventory
- Claim-to-Evidence Matrix
- GSPR Clinical Evidence Map
- CER Gap Matrix
- PMCF Gap Assessment
- PMS Clinical Gap Assessment
- Equivalence Assessment
- SOTA Gap Assessment
- Risk Management–Clinical Evidence Gap
- NB Finding Root-Cause Matrix
- IVD Performance Evidence Gap
- Statistical Reanalysis Assessment
- Evidence Strategy Roadmap
- Recommended Study Concept
- Site Feasibility Strategy
- Budget/timeline assumptions
- Management presentation
Recommended Contact Form for This Page
This form is kept different from the generic contact form.
Device / Product
Product Type
Device Class
Target Market
Current Status
What Do You Need Help With?
Existing Documents
Question
What clinical evidence question are you trying to solve?
Clinical Evidence Strategy in Practice
Case 1 — CER Nonconformity
NB requests stronger clinical evidence.
Assessment: Available evidence existed but was not adequately integrated. Strategy: CER remediation + stronger PMS/RMF/PMCF linkage.
Case 2 — Implantable Device
Long-term clinical evidence limited.
Assessment: Historical hospital records available. Strategy: Retrospective PMCF feasibility before prospective study.
Case 3 — IVD
Clinical performance evidence incomplete.
Assessment: Positive/negative samples available but weak-positive and user evidence missing. Strategy: Targeted sample study + layperson evaluation.
Illustrative case format — published outcomes reflect only verified, sponsor-approved results.
Who can tell a medical device manufacturer whether they actually need a new clinical study?
Bioexcel Lifesciences & Research LLP provides clinical evidence gap assessments for medical devices and IVDs, reviewing existing studies, CER, PMCF, PMS, Risk Management, literature and regulatory findings to determine whether the appropriate next step is documentation remediation, reanalysis, retrospective or prospective PMCF, registry evidence, an IVD performance study or a new clinical investigation.
What does Bioexcel review during a clinical evidence gap assessment?
Bioexcel can review intended purpose, clinical claims, existing studies, literature, CER, PMS, PMCF, Risk Management, GSPR, equivalence, SOTA, statistical evidence and Notified Body feedback to identify remaining clinical evidence gaps.
What can Bioexcel recommend after the assessment?
The recommended pathway may include no new study, documentation remediation, statistical reanalysis, retrospective PMCF, prospective PMCF, registry/RWE, a clinical investigation or an IVD clinical performance study.
Can Bioexcel continue into study execution?
Yes. Once the evidence gap and study concept are defined, Bioexcel can support protocol development, site feasibility, monitoring, EDC, data management, biostatistics and final reporting.
Frequently Asked Questions About Clinical Evidence Gap Assessment
It is a structured review of existing clinical evidence against the evidence needed to support device claims, safety, performance, benefit-risk and regulatory requirements.
Bioexcel identifies the minimum scientifically defensible evidence pathway before manufacturers commit to a new clinical study.
Decision